RS67760B1 - Kanabinoidna kompozicija i njena primena u pripremi leka za lečenje neurodegenerativnih bolesti kao što su parkinsonova bolest i alchajmerova bolest - Google Patents

Kanabinoidna kompozicija i njena primena u pripremi leka za lečenje neurodegenerativnih bolesti kao što su parkinsonova bolest i alchajmerova bolest

Info

Publication number
RS67760B1
RS67760B1 RS20260204A RSP20260204A RS67760B1 RS 67760 B1 RS67760 B1 RS 67760B1 RS 20260204 A RS20260204 A RS 20260204A RS P20260204 A RSP20260204 A RS P20260204A RS 67760 B1 RS67760 B1 RS 67760B1
Authority
RS
Serbia
Prior art keywords
disease
parkinson
alzheimer
drug
preparation
Prior art date
Application number
RS20260204A
Other languages
English (en)
Inventor
Chendong Zou
Hei Tai
Guijiang Wang
Wan Xiao
Sui Huang
Original Assignee
Hempire Shanghai Pharmaceutical R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hempire Shanghai Pharmaceutical R&D Ltd filed Critical Hempire Shanghai Pharmaceutical R&D Ltd
Publication of RS67760B1 publication Critical patent/RS67760B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RS20260204A 2021-08-11 2021-11-26 Kanabinoidna kompozicija i njena primena u pripremi leka za lečenje neurodegenerativnih bolesti kao što su parkinsonova bolest i alchajmerova bolest RS67760B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110916566.9A CN113368086B (zh) 2021-08-11 2021-08-11 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
PCT/CN2021/133379 WO2023015772A1 (zh) 2021-08-11 2021-11-26 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
EP21953377.5A EP4205732B1 (en) 2021-08-11 2021-11-26 Cannabinoid composition and application thereof in preparation of drug for treating neurodegenerative diseases such as parkinson's disease and alzheimer's disease

Publications (1)

Publication Number Publication Date
RS67760B1 true RS67760B1 (sr) 2026-03-31

Family

ID=77576733

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20260204A RS67760B1 (sr) 2021-08-11 2021-11-26 Kanabinoidna kompozicija i njena primena u pripremi leka za lečenje neurodegenerativnih bolesti kao što su parkinsonova bolest i alchajmerova bolest

Country Status (24)

Country Link
US (1) US11497719B1 (sr)
EP (1) EP4205732B1 (sr)
JP (1) JP7220818B1 (sr)
KR (1) KR102623984B1 (sr)
CN (1) CN113368086B (sr)
AU (1) AU2021459955B2 (sr)
CA (1) CA3192406C (sr)
DK (1) DK4205732T3 (sr)
ES (1) ES3062607T3 (sr)
FI (1) FI4205732T3 (sr)
HR (1) HRP20260264T1 (sr)
IL (1) IL302085A (sr)
LT (1) LT4205732T (sr)
MA (1) MA65559B1 (sr)
MD (1) MD20250033A2 (sr)
MX (1) MX2024001818A (sr)
NZ (1) NZ807398A (sr)
PL (1) PL4205732T3 (sr)
PT (1) PT4205732T (sr)
RS (1) RS67760B1 (sr)
SI (1) SI4205732T1 (sr)
SM (1) SMT202600078T1 (sr)
WO (1) WO2023015772A1 (sr)
ZA (1) ZA202400378B (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
KR20240036952A (ko) * 2022-09-14 2024-03-21 주식회사 네오켄바이오 칸나비노이드를 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 및 이의 용도
US20240350592A1 (en) * 2023-04-12 2024-10-24 Xygenyx Inc. Composition and methods of treatment using synergistically-enhanced supplementation
WO2026018132A1 (en) * 2024-07-16 2026-01-22 Buzzelet Development And Technologies Ltd. Cannabinoid-containing compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
ES2359168T3 (es) * 2007-10-02 2011-05-19 Vivacell Biotechnology España S.L. Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias.
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
AU2017319702B2 (en) * 2016-09-02 2024-11-14 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
CN109963595B (zh) * 2016-10-11 2023-02-03 Gbs全球生物制药公司 用于治疗神经退行性疾病的含有大麻素的复合混合物
GB2559774B (en) * 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
EP3589129A4 (en) * 2017-03-01 2020-11-25 Canopy Growth Corporation TARGETEDLY SELECTED COMPOSITIONS CONTAINING PURIFIED CANNABINOIDS AND / OR PURIFIED TERPENES
CN107095302A (zh) * 2017-05-09 2017-08-29 何宗迅 大麻素类混合物及其在食品工业中的应用
US12324789B2 (en) * 2017-08-28 2025-06-10 Apirx Pharmaceutical Usa, Llc Method to treat psoriasis
US11484510B2 (en) * 2017-08-28 2022-11-01 Apirx Pharmaceutical Usa, Llc Method to treat vitiligo
US11622956B1 (en) * 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
CN113116869B (zh) * 2019-12-31 2022-08-23 汉义生物科技（北京）有限公司 一种预防和/或治疗抑郁的组合物
WO2022043961A1 (en) * 2020-08-31 2022-03-03 Nelson Mandela University Cannabinoid combinations and their use in the treatment of cancer
GB202101732D0 (en) * 2021-02-08 2021-03-24 Tts Pharma Ltd A cannabinoid mixture
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
EP4408404A4 (en) * 2021-09-28 2025-10-29 Gbs Global Biopharma Inc Formulations containing cannabinoids for Parkinsonian movement disorders

Also Published As

Publication number Publication date
CN113368086B (zh) 2021-12-03
MD20250033A2 (ro) 2025-08-31
IL302085A (en) 2023-06-01
CN113368086A (zh) 2021-09-10
ZA202400378B (en) 2024-03-27
KR20230123010A (ko) 2023-08-22
PT4205732T (pt) 2026-02-24
MA65559A1 (fr) 2025-02-28
NZ807398A (en) 2024-05-31
LT4205732T (lt) 2026-03-25
HRP20260264T1 (hr) 2026-04-10
FI4205732T3 (fi) 2026-03-12
EP4205732A1 (en) 2023-07-05
WO2023015772A1 (zh) 2023-02-16
MA65559B1 (fr) 2025-12-31
CA3192406C (en) 2024-04-09
US11497719B1 (en) 2022-11-15
JP7220818B1 (ja) 2023-02-10
MX2024001818A (es) 2024-03-06
SI4205732T1 (sl) 2026-04-30
AU2021459955A1 (en) 2023-04-13
KR102623984B1 (ko) 2024-01-11
DK4205732T3 (da) 2026-02-23
JP2023026291A (ja) 2023-02-24
PL4205732T3 (pl) 2026-04-07
EP4205732B1 (en) 2026-01-28
AU2021459955B2 (en) 2023-09-14
ES3062607T3 (en) 2026-04-13
SMT202600078T1 (it) 2026-03-09
CA3192406A1 (en) 2023-02-16
EP4205732A4 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
SI4205732T1 (sl) Sestava kanabinoidov in njena uporaba pri pripravi zdravila za zdravljenje nevrodegenerativnih bolezni, kot sta parkinsonova bolezen in alzheimerjeva bolezen
EP4196113A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT OF PARKINSON’S DISEASE
WO2012080729A3 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
WO2008061795A3 (en) N- (methyl) -1h- pyrazol- 3 -amine, n- (methyl) -pyridin-2-amine and n- (methyl) -thiaz0l-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
BR112016025997A8 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
AU2021318589A1 (en) Use of CD44 antibody in preparation of medicine for treating Parkinson's disease
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications
Zhu et al. Develop potential multi-target drugs by self-assembly of quercetin with amino acids and metal ion to achieve significant efficacy in anti-Alzheimer’s disease
EP4370131A4 (en) METHODS FOR TREATING ALZHEIMER'S DISEASE
MX2010008706A (es) Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales.
EP4087654A4 (en) TREATMENT OF ALZHEIMER'S DISEASE
KR102467285B9 (ko) 우황청심환을 포함하는 파킨슨 질환 예방 또는 치료용 약학 조성물
ZA200700945B (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
IL295948B1 (en) A pharmaceutical preparation for the prevention or treatment of diabetes and related metabolic diseases
HK40098773A (en) Compositions and methods for the treatment of alzheimer's disease
RU2013139704A (ru) Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера
WO2011015646A3 (en) Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
IL271795A (en) A screening platform to identify drugs or medical substances for the treatment of Alzheimer's disease
EP3900719A4 (en) COMPOSITION CONTAINING AN AMINO ACID FERROUS PARTICLE AND ITS USE IN THE PREPARATION OF A PHARMACEUTICAL PRODUCT FOR THE TREATMENT OR IMPROVEMENT OF A PANCREAS-RELATED DISEASE
IL315725A (en) Methods and preparations for the treatment of Parkinson's disease
HK40097912A (en) Pharmaceutical composition for the treatment of alzheimer's disease or dementia
HK40084051A (en) Treatment of alzheimer's disease
CA3266847A1 (en) VALACYCLOVIR AND CELECOXIB FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND COVID-19
HK40111619A (en) Methods of treating alzheimer's disease
WO2024192296A8 (en) Compositions and methods for treating alzheimer's disease